Mesothelioma Blood Tests: Hidden Spots Scans Miss
- Immunotherapy before and after surgery may benefit people with operable diffuse pleural mesothelioma.
- Mesothelioma is a rare cancer affecting the lining of organs, frequently enough linked to asbestos exposure.
- The study explored combining immunotherapy with surgery, assessing feasibility and safety.
Immunotherapy before and after surgery may benefit people with operable diffuse pleural mesothelioma.
Mesothelioma is a rare cancer affecting the lining of organs, frequently enough linked to asbestos exposure.
The study explored combining immunotherapy with surgery, assessing feasibility and safety.
Circulating tumor DNA (ctDNA) testing helped detect microscopic cancer signs missed by imaging, predicting treatment response.
This was a Phase II clinical trial, focused on treatment delivery and benefit-risk assessment.
Research was conducted at Georgetown’s Lombardi Extensive Cancer Center and Johns Hopkins Kimmel Cancer Center.
The study was presented at the 2025 World Conference on Lung Cancer and published in Nature Medicine (DOI: 10.1038/S41591-025-03958-3).